Cognition Therapeutics schedules Type C FDA meeting on zervimesine Phase 3 DLB endpoints
Cognition Therapeutics scheduled a Type C meeting with the FDA for October 20, 2026 to align on endpoints for its Phase 3 trial of zervimesine (CT1812) in DLB.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cognition Therapeutics schedules FDA Type C meeting for Phase 3 endpoints
Cognition Therapeutics (CGTX) scheduled a Type C meeting with the FDA to align on endpoints for its Phase 3 trial of zervimesine (CT1812) in DLB.